Answers are grounded in this paper and cite their sources.
Objective: It has been previously demonstrated that the development of numerous autoimmune and neurological diseases in humans, as well as in experimental autoimmune encephalomyelitis mice, results from a disruption in the differentiation profile of bone marrow stem cells (BMSCs). This disruption leads to inflammation and the emergence of antibodies with diverse catalytic activities. We hypothesized that the development of Alzheimer’s disease (AD), particularly at its early stages, may also be associated with an altered differentiation profile of BMSCs. Methods: One of the earliest and statistically reliable indicators of developing autoimmune reactions is the appearance of abzymes—catalytically active antibodies—in the blood of patients and mice, whereas they are absent in healthy donors. Immunoglobulin G (IgG) antibodies targeting five individual histones (H1, H2A, H2B, H3, and H4) were isolated from the blood of 5xFAD mice at various stages of AD progression. Results: It has been demonstrated that the development of AD in 5xFAD mice begins with an impairment of the BMSC differentiation profile. The isolated antibodies effectively hydrolyzed all five histones. The progression of AD over 10, 20, 40, and 100 days was associated with the development of autoimmune reactions, reflected by a steady increase in the number of cleavage sites across the five histones. Depending on the histone, this number rose from 1 to 9 cleavage sites at early time points to 16–18 sites by day 100, corresponding to advanced pathology. Conclusions: Potential reasons for the marked differences in the specific types and numbers of histone cleavage sites during the progression of Alzheimer’s disease are discussed.
No takes yet. Share an insight, caveat, or question.
Urusov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: